BASEL, SWITZERLAND--(Marketwire - September 11, 2012) -
Basilea Pharmaceutica AG /
Basilea reports presentation of new data on investigational anti-infectives
isavuconazole, ceftobiprole and BAL30072 at ICAAC
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, September 11, 2012 - Basilea Pharmaceutica Ltd.
(SIX: BSLN)
today reported that new data on anti-infectives isavuconazole, ceftobiprole
and
BAL30072 are being presented at the 2012 Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), taking place from September
9 to
12, 2012, in San Francisco, USA.
Basilea's Chief Scientific Officer Dr. Laurenz Kellenberger commented: "The
rising tide of multidrug-resistant bacteria and the still unacceptably high
mortality related to serious infections highlight the urgent need for novel
antimicrobials. The data presented at ICAAC further substantiate the
promising
profiles of these innovative product candidates for addressing this high
unmet
medical need."
Key presentations include the following:
Posters on isavuconazole
Isavuconazole (ISA) Pharmacodynamic (PD) Target Determination for C.
albicans
(CA) in an In Vivo Neutropenic Murine Model of Invasive Candidiasis (IC) -
A.
Lepak, K. Marchillo,
j. Cabezas, D.R. Andes; A-1931
In Vitro Activity of Isavuconazole against Cryptococcus Isolates - A Pooled
Analysis from 3 Studies - J.I. Smart, M.E. Jones, L.L. Kovanda; M-331
Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of CYP3A4
Substrate Midazolam in Healthy Volunteers - A. Desai, N. Zadeikis, H.
Pearlman,
D. Kowalski,
R. Townsend; A-1936
In Vitro Activity of Isavuconazole against a Worldwide Collection of 237
Aspergillus terreus Isolates and Compared with 7 Other Aspergillus Active
Antifungal Drugs Tested with EUCAST and CLSI Methodology - J.F. Meis, J.W.
Mouton, J.P. Bouchara, A. Chakrabarti,
P. Gaustad, J.V. Guinea-Ortega, J. Houbraken, R.A. Samson, K. Grif, C.
Lass-Floerl, C.H. Klaassen; M-332
Posters on ceftobiprole
%fT > MIC Predicts Probability of Microbiological Outcome in the Treatment
of
Nosocomial Pneumonia by Ceftobiprole - A.E. Muller, N. Punt, J.W. Mouton;
A-624
Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment
of
Ceftobiprole in Nosocomial Pneumonia Patients: A Validation Study - A.
Muller,
A.H. Schmitt-Hoffmann, N. Punt, J.W. Mouton; A-624a
Posters on BAL30072
In Vitro Activity of BAL30072 against Contemporary Clinical Isolates of
Gram-Negative Bacteria (GNB) from New York City including
Multidrug-Resistant (MDR)
Isolates - D. Landman, M. Singh, B. El-Imad, E. Miller, T. Win, J. Quale;
F-841
Antimicrobial Activity of BAL30072, Alone and in Combination with Meropenem
Tested Against Gram-Negative Bacteria Causing Serious Infections in
Hospitals
from China, India, Latin America and South East Asia-Pacific - P.R.
Rhomberg,
K.A. Fedler, R.K. Flamm, R.N. Jones, H.S. Sader; E-193
Comparative Efficacy of BAL30072, Aztreonam, Meropenem and Ceftazidime and
Effects of Dose Fractionation in a Murine Thigh Infection Model - J.K.
gould, A.
Sattar, G.M. Daws, L.J. Payne, J. Spikermann, W. StubbinGs, A.
SchmiTt-HOffmanN, M.G.P. Page, P.a. Warn;
F-842
Urinary Antibacterial Activity of BAL30072 against Uropathogens After IV
Administration - F.M.E. Wagenlehner, B. Blenk, C. Wagenlehner, H. Blenk,
K.G.
Naber;
A-1285
For further information please visit www.icaac.org.
About isavuconazole
Isavuconazole is a novel intravenous and oral broad-spectrum antifungal. In
collaboration with Astellas Pharma Inc., isavuconazole is being
investigated in
a phase III program for the treatment of severe invasive and
life-threatening
fungal infections. The drug demonstrated excellent in-vitro and in-vivo
coverage
of a broad range of yeasts (such as Candida species) and molds (such as
Aspergillus species) as well as less prevalent but often fatal molds such
as
Zygomycetes spp. It has reliable and predictable dosing, allowing a switch
from
IV administration to a convenient once daily oral dose and has the
potential to
overcome many of the limitations of current treatment options.
About ceftobiprole
Ceftobiprole is a novel broad-spectrum antibiotic for the potential
treatment of
severe, multidrug-resistant bacterial infections. The drug has activity
against
a wide range of Gram-positive bacteria, including the MRSA 'superbug' and
clinically relevant Gram-negative bacteria. Ceftobiprole has met the study
endpoints in several phase III trials and has shown a typical cephalosporin
safety profile. A Marketing Authorization Application has been submitted in
Europe through the decentralized procedure.
About BAL30072
BAL30072 is a novel investigational bactericidal sulfactam antibiotic in
phase
I, specifically targeting multidrug-resistant Gram-negative bacteria. The
innovative antibacterial drug has demonstrated broad in-vitro and in-vivo
coverage of Gram-negative pathogens including multidrug-resistant
Pseudomonas
aeruginosa and Acinetobacter baumannii. It has robust activity against
common
strains of bacteria that produce antibiotic-inactivating enzymes including
extended-spectrum beta-lactamases (ESBL) and metallo-beta-lactamases such
as the
New Delhi metallo-beta-lactamase 1 (NDM-1). In addition, BAL30072 has been
shown
to enhance the activity of antibiotics from the penem class.
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and
listed on
the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
and
development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd. ("Basilea") the company focuses on innovative
pharmaceutical
products in the therapeutic areas of bacterial infections, fungal
infections and
oncology, targeting the medical challenge of rising resistance and
non-response
to current treatment options.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different
from
any future results, performance or achievements expressed or implied by
such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
future
events or otherwise.
This press release can be downloaded from www.basilea.com.
Press release (PDF) :
http://hugin.info/134390/R/1640346/528063.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1640346]
